About Neosil
Neosil is a Healthcare company based in Palo Alto (United States) founded in 2003, and was acquired by Peplin in June 2008. Specialty dermatology pharmaceuticals were developed by US-based Neosil until acquisition. Neosil has raised $32 million across 2 funding rounds from investors including Hercules Capital, Burrill and Company and Peplin. Its chief executive, as recorded, is Gene Bauer. The company was acqui-hired. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Castle Creek Pharma and Dermavant; 3 of its 3 listed competitors have raised funding.
Company details
Neosil was established in 2003 in Palo Alto, United States, as a specialty pharmaceutical company centered on dermatology. Operations involved the development of products like NEOSH101 for hair growth and broad-spectrum anti-microbial agents targeting acne. The firm was led by CEO Gene Bauer. Acquisition by Peplin occurred in October 2008, concluding independent activities.
- Headquarters Palo Alto, United States
- Stage Acquired
- SectorsHealthcare
- Website neosil.com
- Acquired by Peplin (Jun 2008)
- Total Equity Funding$32M (USD)
in 2 rounds
- Latest Funding Round$10M (USD), Debt – Venture
May 2007
- InvestorsHercules Capital
& 3 more
- Acquired byPeplin
(Jun 2008)
Funding Insights of Neosil
Neosil has successfully raised a total of $32M across 2 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $10 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32M
- Total Rounds 2
- Last Round Debt – Venture — $10M
- First Round $32M
(Nov 2004)
- Investors Count 3
All 2 funding rounds of Neosil with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2007 | $10M | Debt – Venture | – | – | |
| Nov 2004 | $32M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Neosil
Neosil has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Burrill and Company and Peplin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Topical gel for the treatment of actinic (solar) keratosis. | 1999 | peplin.com | Emeryville, United States |
Investor details for Neosil
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neosil
1 people are tracked at Neosil (1 in leadership).
| Name | Role | Group |
|---|---|---|
Gene Bauer | CEO | Leadership |
Complete people profiles for Neosil
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Neosil
4 dated milestones of Neosil across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Neosil is founded.
- Funding First funding round of $32.0M.
- Funding Latest funding round, Debt – Venture, of $10.0M.
- Exit Acquired by Peplin.
Competitors of Neosil
Neosil has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Dermavant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. |
Detailed competitors of Neosil
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Neosil (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neosil
Complete news archive for Neosil
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neosil
Neosil was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Neosil is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Gene Bauer is the CEO of Neosil, as recorded in our data.
Neosil is a funded company, having raised a total of $32M across 2 funding rounds to date. The company's 1st funding round was a Series A of $32M, raised on Nov 2004.
Neosil was established in 2003 in Palo Alto, United States, as a specialty pharmaceutical company centered on dermatology. Operations involved the development of products like NEOSH101 for hair growth and broad-spectrum anti-microbial agents targeting acne. The firm was led by CEO Gene Bauer. Acquisition by Peplin occurred in October 2008, concluding independent activities.
Neosil's top competitors include Revance Therapeutics, Dermavant and Castle Creek Pharma.
Neosil has 4 investors. Key investors include Hercules Capital, Burrill and Company, Peplin, and Turmeric Acquisition Corp.
Yes. Neosil was acquired by Peplin in June 2008.